Clinical Trial Update: Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating nab-paclitaxel versus topotecan as second-line therapy for extensive-stage small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Topotecan (topotecan)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN